http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17689807

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't
issn 2051-1426
issueIdentifier 3
pageRange e004291corr1-
publicationName Journal for ImmunoTherapy of Cancer
startingPage e004291corr1
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_953fb12802c20a3ec2046173c3fe8650
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f
bibliographicCitation Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, Zhu L, Shen Y, Zhang H, Sun Y, Chen H, Yu B, Zhang R, Shao J, Zhang M, Li Z. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022 Mar;10(3):e004291. doi: 10.1136/jitc-2021-004291.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8fcddad8248fc5e6325f8a7acd3a685
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2218d5ef87ec369ebd0f6d8eff3bceb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3542-0905
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5086-5334
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_49a8e795465074f531d8270407452fe0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3390cdeb7e50ce3773e53e70d795bff9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f995265ebb6ad5583c07cdae93efced
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0901c2226a4565900d71d521e5e79e42
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2f7bddcb5b2a4ac4d1b5452f20ab9e18
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d0398f6585fd42cf7620dd8b7014e72
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f5784c937e35472e145b85db24debf3a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b38cf0a4ead6b9bcba33e6ce7d0e4bf5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ff7c8f72b4b1c6fda45a6b1c65f38183
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fb48b49123f2581816c21e8b7294dbd5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_893d898f8650cbbc7708b440c492b9e9
date 202203
identifier https://doi.org/10.1136/jitc-2021-004291corr1
https://doi.org/10.1136/jitc-2021-004291
https://pubmed.ncbi.nlm.nih.gov/35672079
https://pubmed.ncbi.nlm.nih.gov/PMC9174757
https://pubmed.ncbi.nlm.nih.gov/35338088
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/41915
https://portal.issn.org/resource/ISSN/2051-1426
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Correction: Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
discusses http://id.nlm.nih.gov/mesh/M000651317
http://id.nlm.nih.gov/mesh/M0556300
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8382
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36314
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6658
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID426756

Total number of triples: 45.